Jefferies Group LLC bought a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 72,500 shares of the biopharmaceutical company’s stock, valued at approximately $2,591,000. Other large investors also recently made changes to their […]
Cytokinetics Incorporated (NASDAQ:CYTK) went down by -1.68% from its latest closing price compared to the recent 1-year high of $47.60. The company’s stock price has collected 3.59% of gains in the last five trading sessions. Press Release reported on 12/20/21 that Cytokinetics and JI XING Announc
At the end of the latest market close, Cytokinetics Incorporated (CYTK) was valued at $40.83. In that particular session, Stock kicked-off at the price of $41.22 while reaching the peak value of $44.56 and lowest value recorded on the day was $41.04. The stock current value is $44.02.Recently in New
Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and.